Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors

Author: Galsky Matthew  

Publisher: Springer Publishing Company

ISSN: 0167-6997

Source: Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 695-701

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content